Clinical trials have demonstrated the significant potential of SPT-300, an oral prodrug of the neurosteroid allopregnanolone. The Glyph™ platform enhances oral bioavailability, allowing SPT-300 to retain the activity and potency of natural allopregnanolone.
SPT-300 has shown efficacy in reducing stress-induced cortisol levels in a Phase 2a trial. This result supports Seaport Therapeutics’ planned studies in mood and anxiety disorders, including anxious depression.
Data from a Phase 1 trial indicates that SPT-300 is well-tolerated and has a favorable safety profile. Oral bioavailability was found to be nine times higher than published data for oral allopregnanolone.
The Glyph™ platform enables SPT-300 to be absorbed like a dietary fat through the lymphatic system, bypassing first-pass metabolism. This approach addresses the naturally low bioavailability of allopregnanolone and preserves its therapeutic effects.
SPT-300 has the potential to make a significant difference for patients with depression, anxiety, and other neuropsychiatric conditions. It demonstrates the versatility of the Glyph™ platform in overcoming obstacles in neuropsychiatric drug development.
The findings from SPT-300 clinical trials provide evidence for its core mechanisms and therapeutic potential. Seaport Therapeutics plans to advance SPT-300 into later-stage clinical studies to further validate its efficacy and safety.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
